| 2010 |
Rubin MR, Dempster DW, Kohler T, Stauber M, Zhou H, Shane E, Nickolas T, Stein E, Sliney J Jr, Silverberg SJ, Bilezikian JP, Müller R. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. January 2010;46(1):190-195. |
9 |
7 |
| 2001 |
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetić K, Müller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. October 2001;16(10):1846-1853. |
53 |
33 |
| 2008 |
Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. December 2008;23(12):1974-1982. |
39 |
28 |
| 2010 |
Liu XS, Zhang XH, Sekhon KK, Adams MF, McMahon DJ, Bilezikian JP, Shane E, Guo XE. High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. J Bone Miner Res. April 2010;25(4):746-756. |
45 |
33 |
| 2014 |
Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP. Trabecular bone score: a noninvasive analytical method based upon the dxa image. J Bone Miner Res. March 2014;29(3):518-530. |
39 |
29 |
| 2020 |
Cusano NE, Rubin MR, Williams JM, Agarwal S, Tabacco G, Tay D, Majeed R, Omeragic B, Bilezikian JP. Changes in skeletal microstructure through four continuous years of rhPTH(1–84) therapy in hypoparathyroidism. J Bone Miner Res. July 2020;35(7):1274-1281. |
2 |
0 |
| 2022 |
Naciu AM, Tabacco G, Bilezikian JP, Santonati A, Bosco D, Incognito GG, Gaspa G, Manfrini S, Falchetti A, Trimboli P, Mazziotti G, Napoli N, Sanson G, Cesareo R, Vescini F, Palermo A. Calcium citrate versus calcium carbonate in the management of chronic hypoparathyroidism: a randomized, double-blind, crossover clinical trial. J Bone Miner Res. July 2022;37(7):1251-1259. |
1 |
1 |
| 2022 |
Bilezikian JP, Khan AA, Clarke BL, Mannstadt M, Potts JT, Brandi ML. The Fifth International Workshop on the Evaluation and Management of Primary Hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2290-2292. |
0 |
0 |
| 2022 |
Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE-H, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML; International Workshop on Primary Hyperparathyroidism. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res. November 2022;37(11):2293-2314. |
3 |
0 |
| 2022 |
Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, Chang Y, Zhang M, Guyatt G, Tangamornsuksun W, Zhang Y, Manja V, Bakaa L, Couban RJ, Brandi ML, Clarke B, Khan AA, Mannstadt M, Bilezikian JP. The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials. J Bone Miner Res. November 2022;37(11):2351-2372. |
3 |
0 |
| 2022 |
Bilezikian JP, Silverberg SJ, Bandeira F, Cetani F, Chandran M, Cusano NE, Ebeling PR, Formenti AM, Frost M, Gosnell J, Lewiecki EM, Singer FR, Gittoes N, Khan AA, Marcocci C, Rejnmark L, Ye Z, Guyatt G, Potts JT. Management of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2391-2403. |
3 |
0 |
| 2022 |
Yao L, Guyatt G, Ye Z, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Khan AA. Methodology for the guidelines on evaluation and management of hypoparathyroidism and primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2404-2410. |
5 |
0 |
| 2022 |
Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Potts JJ, Mannstadt M; International Workshop on Primary Hyperparathyroidism. The Second international Workshop on the Evaluation and Management of Hypoparathyroidism. J Bone Miner Res. December 2022;37(12):2566-2567. |
0 |
0 |
| 2022 |
Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL, Rejnmark L, Shoback DM, Potts JT, Guyatt GH, Mannstadt M. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J Bone Miner Res. December 2022;37(12):2568-2585. |
3 |
0 |
| 2022 |
Van Uum S, Shrayyef M, M'Hiri I, Dandurand K, Ali DS, Bilezikian JP, Collins MT, Mannstadt M, Rubin MR, Siggelkow H, Tabacco G, Tay Y-KD, Vokes T, Winer KK, Yao L, Guyatt G, Rejnmark L, Khan AA. Initial assessment and monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J Bone Miner Res. December 2022;37(12):2630-2641. |
4 |
0 |
| 2022 |
Yao L, Hui X, Li M, Li J, Ahmed MM, Lin C, Kandi M, Sreekanta A, Makhdami N, Tamilselvan D, Ali DS, Dandurand K, Yang K, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Rejnmark L, Khan AA, Guyatt G. Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review. J Bone Miner Res. December 2022;37(12):2642-2653. |
5 |
0 |
| 2022 |
Yao L, Li J, Li M, Lin C, Hui X, Tamilselvan D, Kandi M, Sreekanta A, Makhdami N, Ali DS, Dandurand K, Yang K, Bilezikian JP, Brandi ML, Clarke BL, Mannstadt M, Rejnmark L, Khan AA, Guyatt G. Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis. J Bone Miner Res. December 2022;37(12):2654-2662. |
4 |
0 |
| 2022 |
Khan AA, Guyatt G, Ali DS, Bilezikian JP, Collins MT, Dandurand K, Mannstadt M, Murphy D, M'Hiri I, Rubin MR, Sanders R, Shrayyef M, Siggelkow H, Tabacco G, Tay Y-KD, Van Uum S, Vokes T, Winer KK, Yao L, Rejnmark L. Management of hypoparathyroidism. J Bone Miner Res. December 2022;37(12):2663-2677. |
5 |
0 |
| 2023 |
Bilezikian JP, Fraenkel M, Tripto-Shkolnik L, Rizzoli R, Siris E. In memoriam: Uri A. Liberman, 1935–2022. J Bone Miner Res. April 2023;38(4):455-456. |
0 |
0 |
| 2023 |
Agarwal S, McMahon DJ, Chen J, Brossfield AV, Fernando J, Bilezikian JP, Cusano NE, Rubin MR. The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH(1-84). J Bone Miner Res. April 2023;38(4):480-492. |
0 |
0 |
| 2023 |
Civitelli R, Bilezikian JP, Potts JT, Stern PH. In memoriam: william a. peck, md. J Bone Miner Res. June 2023;38(6):809-811. |
0 |
0 |
| 2003 |
Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. January 2003;88(3):1150-1156. |
30 |
24 |
| 2011 |
Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest. November 2011;34(10):801-810. |
14 |
14 |
| 2003 |
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. NEJM. September 25, 2003;349(13):1207-1215. |
53 |
47 |
| 2005 |
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. NEJM. August 11, 2005;353(6):555-565. |
34 |
26 |
| 2007 |
Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. NEJM. August 30, 2007;357(9):905-916. |
31 |
31 |
| 2011 |
Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV. Interpretation and use of FRAX in clinical practice. Osteoporos Int. September 2011;22(9):2395-2411. |
32 |
20 |